Recent perspectives on the age-related decline of testosterone

Journal of Men's Health

Volumn 5, Issue 1, 2008, Pages 86-93

  Gooren, Louis ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

LOH; Testosterone

Indexed keywords

LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGING; ALCOHOLISM; ANDROGEN DEFICIENCY; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; FRACTURE; HORMONE ACTION; HUMAN; HYPOGONADISM; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MEN'S HEALTH; METABOLIC SYNDROME X; OBESITY; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PSYCHOLOGICAL ASPECT; TESTOSTERONE BLOOD LEVEL;

EID: 40149087198     PISSN: 18756867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jomh.2007.12.003     Document Type: Article

References (54)

1. Werner A. The male climacteric. JAMA 112 (1939) 1441-1443
2. Heller C., and Myers G.B. The male climacteric, its symptomatology, diagnosis and treatment. JAMA 126 (1944) 472-477
3. McGavack T. The male climacterium. J Am Geriatric Soc 3 9 (1955) 639-655
4. McLachlan R.I., and Allan C.A. Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal posts?. J Clin Endocrinol Metab 89 12 (2004) 5916-5919
5. Handelsman D.J., and Liu P.Y. Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab 16 2 (2005) 39-45
6. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 8 2 (2005) 56-58
7. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48 1 (2005) 1-4
8. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91 6 (2006) 1995-2010
9. Saad F., Gooren L.J., Haider A., and Yassin A. A dose-response study of testosterone on sexual dysfunction and on features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 29 (2008) 102-105
10. Kaufman J.M., and Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26 6 (2005) 833-876
11. Gray A., Feldman H.A., McKinlay J.B., and Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73 5 (1991) 1016-1025
12. Feldman H.A., Longcope C., Derby C.A., Johannes C.B., Araujo A.B., Coviello A.D., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 87 2 (2002) 589-598
13. Mohr B.A., Guay A.T., O'Donnell A.B., and McKinlay J.B. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 62 1 (2005) 64-73
14. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., and McKinlay J.B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 23 4 (2000) 490-494
15. Mohr B.A., Bhasin S., Link C.L., O'Donnell A.B., and McKinlay J.B. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 155 3 (2006) 443-452
16. Rodriguez A., Muller D.C., Metter E.J., Maggio M., Harman S.M., Blackman M.R., et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92 9 (2007) 3568-3572
17. Kaplan S.A., Meehan A.G., and Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 176 4 Pt 1 (2006) 1524-1527 discussion 7-8
18. Allan C.A., Strauss B.J., Burger H.G., Forbes E.A., and McLachlan R.I. The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Med J Aust 185 8 (2006) 424-427
19. Svartberg J., Midtby M., Bonaa K.H., Sundsfjord J., Joakimsen R.M., and Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol 149 2 (2003) 145-152
20. Travison T.G., Shabsigh R., Araujo A.B., Kupelian V., O'Donnell A.B., and McKinlay J.B. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study. J Urol 177 1 (2007) 241-246 discussion 6
21. Isidori A.M., and Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 28 3 Suppl (2005) 14-22
22. Shores M.M., Moceri V.M., Gruenewald D.A., Brodkin K.I., Matsumoto A.M., and Kivlahan D.R. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 52 12 (2004) 2077-2081
23. Shores M.M., Matsumoto A.M., Sloan K.L., and Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 15 (2006) 1660-1665
24. Laughlin G.A., Barrett-Connor E., and Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93 (2007) 68-75
25. Araujo A., Kupelian V., Page S.T., Handelsman D.J., Bremner W.J., and McKinlay J.B. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med 167 (2007) 1252-1260
26. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 5 (2004) 1036-1041
27. Smith R.M., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
28. Basaria S., Muller D.C., Carducci M.A., Egan J., and Dobs A.S. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 3 (2006) 581-588
29. Haidar A., Yassin A., Saad F., and Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 10 4 (2007) 189-196
30. Yialamas M.A., Dwyer A.A., Hanley E., Lee H., Pitteloud N., and Hayes F.J. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92 11 (2007) 4254-4259
31. Ryan C.W., Huo D., Bylow K., Demers L.M., Stadler W.M., Henderson T.O., et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 100 1 (2007) 70-75
32. Mhatre A.N., Trifiro M.A., Kaufman M., Kazemi-Esfarjani P., Figlewicz D., Rouleau G., et al. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet 5 2 (1993) 184-188
33. Beilin J., Ball E.M., Favaloro J.M., and Zajac J.D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 25 1 (2000) 85-96
34. Albertelli M.A., Scheller A., Brogley M., and Robins D.M. Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol Endocrinol 20 6 (2006) 1248-1260
35. Zitzmann M., and Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 26 2 (2003) 76-83
36. Zeegers M.P., Kiemeney L.A., Nieder A.M., and Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol Biomarkers Prev 13 11 Pt 1 (2004) 1765-1771
37. Canale D., Caglieresi C., Moschini C., Liberati C.D., Macchia E., Pinchera A., et al. Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin Endocrinol (Oxf) 63 3 (2005) 356-361
38. Zitzmann M., Depenbusch M., Gromoll J., and Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88 5 (2003) 2049-2054
39. Zitzmann M., Depenbusch M., Gromoll J., and Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 89 12 (2004) 6208-6217
40. Crabbe P., Bogaert V., De Bacquer D., Goemaere S., Zmierczak H., and Kaufman J.M. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 92 9 (2007) 3604-3610
41. Kelleher S., Conway A.J., and Handelsman D.J. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89 8 (2004) 3813-3817
42. Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol 4 3 (2007) 161-166
43. Gooren L.J. Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 16 6 (1987) 463-473
44. Bagatell C.J., Heiman J.R., Rivier J.E., and Bremner W.J. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 78 3 (1994) 711-716
45. Woodhouse L.J., Reisz-Porszasz S., Javanbakht M., Storer T.W., Lee M., Zerounian H., et al. Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab 284 5 (2003) E1009-E1017
46. Zitzmann M., Faber S., and Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91 11 (2006) 4335-4343
47. Bancroft J. The endocrinology of sexual arousal. J Endocrinol 186 3 (2005) 411-427
48. Aversa A., Isidori A.M., Spera G., Lenzi A., and Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58 5 (2003) 632-638
49. Araujo A.B., O'Donnell A.B., Brambilla D.J., Simpson W.B., Longcope C., Matsumoto A.M., et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89 12 (2004) 5920-5926
50. O'Donnell A.B., Araujo A.B., and McKinlay J.B. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol 39 7 (2004) 975-984
51. Nieschlag E., Behre H.M., Bouchard P., Corrales J.J., Jones T.H., Stalla G.K., et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10 5 (2004) 409-419
52. Kshirsagar A., Seftel A., Ross L., Mohamed M., and Niederberger C. Predicting hypogonadism in men based upon age, presence of erectile dysfunction, and depression. Int J Impot Res 18 1 (2006) 47-51
53. Black A.M., Day A.G., and Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?. BJU Int 94 7 (2004) 1066-1070
54. Reyes-Vallejo L., Lazarou S., and Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med 4 6 (2007) 1757-1762